Versant debuts biotech working on ‘anger management for the immune system’
抗体药物偶联物免疫疗法
Precision immunology has emerged as one of the hottest fields in drugmaking over the past several years, spurred by new ways to make more potent drugs that don’t trigger as many side effects.
Large drugmakers and venture firms alike have shelled out billions of dollars for promising anti-inflammatory treatments. Johnson & Johnson and Roche both picked up autoimmune drugs in blockbuster deals, while Mirador Therapeutics launched in March with $400 million from investors to develop new autoimmune medicines.
On Thursday, Santa Ana Therapeutics became the latest such startup to emerge, making its debut with $168 million and a trio of programs that riff in new ways on existing ideas like targeting mast cells and stimulating the PD-1 pathway.
”We've been drugging lots of cytokines, trying to modify the biology, and it's worked,” said Peter Emtage, Santa Ana's CEO. ”But the opportunity really comes in when you can identify the culprit cell.”
One of Santa Ana’s drugs, dubbed SAB01, is a so-called bispecific antibody. It is designed to mute the mast cells that drive allergic disease by blocking a protein called c-Kit. But the drug will only do so when it detects another target that’s found on those cells. Past attempts to treat such diseases by inhibiting c-Kit have failed due to side effects triggered by interfering with that protein on other cell types, Santa Ana said.
The company is developing SAB01 for chronic inducible urticaria, a common skin condition, and plans to enter the clinic in 2025.
A second candidate, a PD-1 agonistPD-1 agonist, is also due to enter Phase 1 trials for several inflammatory conditions next year. While checkpoint inhibitors that block PD-1 have proved powerful in treating cancer, SAB03 is meant to keep T cells from activating and preventing the immune system from going into overdrive. Other companies, such as MiroBio, which sold in 2022 to Gilead Sciences, have tried to do something similar.
“We almost think of Santa Ana as doing anger management for the immune system,” said Jerel Davis, a managing director at Versant.
Santa Ana is developing a third medicine that’s similar in concept to an antibody-drug conjugate, but designed to make glucocorticoid drugs safer.
Versant Ventures led Santa Ana’s $43 million Series A round, while GV was the primary backer of its $125 Series B round. Other investors include TPG, a16z, Access Biotechnology and RTW.
Santa Ana’s name has similar origins to another Versant company, Chinook Therapeutics. While the latter took inspiration from the warm, western winds in the Pacific Northwest, Santa Ana’s is named after the desert and mountain winds of Southern California. (Santa Ana is based in Alameda, just a few miles across the bay from South San Francisco, however.)
Versant also recently backed SixPeaks Bio, an obesity drug startup molded as a “build-to-buy” biotech.
'
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。